A Kent and Medway Cancer Network (KMCN) audit of second-line treatment for non-small cell lung cancer

被引：0
|
作者：
Cafferkey, C. [1 ]
Jamal-Hanjani, M. [1 ]
Beesley, S. [1 ]
Cominos, M. [1 ]
Sevitt, T. [1 ]
Taylor, H. [1 ]
Burcombe, R. [1 ]
Shah, R. [1 ]
机构：
[1] Maidstone Hlth Author, Maidstone, Kent, England
来源：
LUNG CANCER | 2010年 / 67卷
关键词：
D O I：
10.1016/S0169-5002(10)70022-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
21
引用
收藏
页码：S7 / S8
页数：2
相关论文
共 50 条
  • [31] Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
    Kang, Hyun Mo
    Lee, Jeong Eun
    Jang, Pil Soon
    Lee, Yun Sun
    Kwon, Sun Jung
    An, Jin Young
    Jung, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2005, 58 (05) : 465 - 472
  • [32] Historical evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
    Lazzari, Chiara
    Bulotta, Alessandra
    Ducceschi, Monika
    Vigano, Maria Grazia
    Brioschi, Elena
    Corti, Francesca
    Gianni, Luca
    Gregorc, Vanesa
    FRONTIERS IN MEDICINE, 2017, 4
  • [33] Palliative second-line systemic treatment of non-small cell lung cancer within a UK cancer centre
    Stokoe, J. M.
    Tuthill, M.
    Balakrishnan, L.
    Brock, J. E.
    LUNG CANCER, 2016, 91 : S27 - S27
  • [34] The experience of immunotherapy in lung cancer: an audit of immunotherapy use as second-line treatment for metastatic non-small cell lung cancer (NSCLC) in the South Tees region
    Hairudin, T.
    Li, L.
    Mansy, T.
    Aynsley, E.
    Kumar, G.
    Masinghe, S.
    Peedell, C.
    LUNG CANCER, 2019, 127 : S43 - S43
  • [35] Second and third line treatment in non-small cell lung cancer
    Favaretto, Adolfo
    Pasello, Giulia
    Magro, Cristina
    Schettino, Clorinda
    Gridelli, Cesare
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 71 (02) : 117 - 126
  • [36] Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
    Corrales, Luis
    Nogueira, Amanda
    Passiglia, Francesco
    Listi, Angela
    Caglevic, Christian
    Giallombardo, Marco
    Raez, Luis
    Santos, Edgardo
    Rolfo, Christian
    FRONTIERS IN MEDICINE, 2017, 4
  • [37] Second-line treatment for non-small cell lung cancer: data from single institution experience
    Lu Shun
    Zhang Yifei
    Cheng Baijun
    Chen Zhiwei
    Li Ziming
    Yu Yongfeng
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S696 - S696
  • [38] From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
    Ettore D’Argento
    Sabrina Rossi
    Giovanni Schinzari
    Antonia Strippoli
    Michele Basso
    Alessandra Cassano
    Carlo Barone
    Current Treatment Options in Oncology, 2016, 17
  • [39] Pharmacoeconomic analysis of erlotinib as second-line treatment of advanced non-small cell lung cancer in Taiwan
    Hsia, T.
    Chang, G.
    Chen, Y.
    Lin, M.
    Su, W.
    Tsai, C.
    Tsai, C.
    Yang, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 375 - 375
  • [40] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
12345